337 related articles for article (PubMed ID: 37495688)
1. Rewiring cancer drivers to activate apoptosis.
Gourisankar S; Krokhotin A; Ji W; Liu X; Chang CY; Kim SH; Li Z; Wenderski W; Simanauskaite JM; Yang H; Vogel H; Zhang T; Green MR; Gray NS; Crabtree GR
Nature; 2023 Aug; 620(7973):417-425. PubMed ID: 37495688
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
3. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
4. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
Luo H; Schmidt JA; Lee YS; Oltz EM; Payton JE
Leuk Lymphoma; 2017 Feb; 58(2):445-456. PubMed ID: 27268204
[TBL] [Abstract][Full Text] [Related]
5. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
[TBL] [Abstract][Full Text] [Related]
6. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
[TBL] [Abstract][Full Text] [Related]
7. B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
McLachlan T; Matthews WC; Jackson ER; Staudt DE; Douglas AM; Findlay IJ; Persson ML; Duchatel RJ; Mannan A; Germon ZP; Dun MD
Mol Cancer Res; 2022 Dec; 20(12):1711-1723. PubMed ID: 36166198
[TBL] [Abstract][Full Text] [Related]
8. Sequential transcription factor targeting for diffuse large B-cell lymphomas.
Cerchietti LC; Polo JM; Da Silva GF; Farinha P; Shaknovich R; Gascoyne RD; Dowdy SF; Melnick A
Cancer Res; 2008 May; 68(9):3361-9. PubMed ID: 18451163
[TBL] [Abstract][Full Text] [Related]
9. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
10. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
[TBL] [Abstract][Full Text] [Related]
11. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Xia Y; Zhang X
Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
[TBL] [Abstract][Full Text] [Related]
13. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
15. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
[TBL] [Abstract][Full Text] [Related]
16. The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma.
Shi Y; Kuai Y; Lei L; Weng Y; Berberich-Siebelt F; Zhang X; Wang J; Zhou Y; Jiang X; Ren G; Pan H; Mao Z; Zhou R
Oncotarget; 2016 Nov; 7(47):77444-77456. PubMed ID: 27764808
[TBL] [Abstract][Full Text] [Related]
17. A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion.
Wang H; Wang A; Hu Z; Xu X; Liu Z; Wang Z
Cancer Immunol Res; 2016 Apr; 4(4):337-44. PubMed ID: 26865454
[TBL] [Abstract][Full Text] [Related]
18. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
[TBL] [Abstract][Full Text] [Related]
19. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
[TBL] [Abstract][Full Text] [Related]
20. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
